Clinical Trial Update: Efficacy and Safety of 4 Weeks Treatment With Inhaled BI 1744 CL in Patients With COPD. [Phase 2]

View source ↗

Summary

This Phase 2 trial evaluates 4 weeks of inhaled BI 1744 CL in patients with chronic obstructive pulmonary disease, reporting on efficacy and safety outcomes.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Asthma
• Chronic Obstructive Pulmonary Disease

Drugs mentioned

• BI 1744 CL

Snippet

Sponsor: Boehringer Ingelheim | Conditions: Pulmonary Disease, Chronic Obstructive, Asthma | Phase 2 | Status: COMPLETED | Results posted: 2014-06-03